(Jan 10, 2022)

Bayer and Mammoth Biosciences forged a strategic collaboration potentially valued at more than $1 billion. The partnership grants the Germany-based pharma giant access to Mammoth’s CRISPR technology to develop in vivo gene-editing therapies.

The companies plan to harness the power of the CRISPR technology across five preselected in vivo indications. While the companies did not disclose all of the indications they intend to target, Bayer said their first focus is liver-targeted diseases.